A carregar...
Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature
BACKGROUND: Programmed death ligand 1 (PD-L1) targeting immunotherapies, as pembrolizumab and nivolumab, have significantly improved outcome in patients with non-small cell lung cancer (NSCLC). Tobacco smoking is the number one risk factor for lung cancer and is linked to 80%–90% of these cancers. S...
Na minha lista:
| Publicado no: | ESMO Open |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6173248/ https://ncbi.nlm.nih.gov/pubmed/30305940 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2018-000406 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|